Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis-MedSci.cn - 梅斯（MedSci）

Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis

Rabe, KF; Martinez, FJ; Ferguson, GT; Wang, C; Singh, D; Wedzicha, J; Trivedi, R; Rose, E; Ballal, S; McLaren, J; Darken, P; Aurivillius, M; Reisner, C; Dorinsky, P

PNEUMOLOGIE, 2021; 75 (): S12

科室
- - 订阅+
  - 更多科室
工具
服务